Ocugen (NASDAQ:OCGN)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $0.58, but opened at $0.56. Ocugen shares last traded at $0.41, with a volume of 5,873,600 shares.
Separately, ValuEngine raised shares of Ocugen from a “hold” rating to a “buy” rating in a report on Friday, November 1st.
The firm has a market capitalization of $8.95 million, a P/E ratio of -0.01 and a beta of 2.92.
In related news, Director Howard C. Draft purchased 68,965 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were bought at an average price of $29.00 per share, with a total value of $1,999,985.00. Also, Director Junge Zhang purchased 31,078 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of $3.09 per share, for a total transaction of $96,031.02. Insiders purchased a total of 109,043 shares of company stock worth $2,112,696 in the last ninety days. 44.70% of the stock is currently owned by insiders.
Ocugen Company Profile (NASDAQ:OCGN)
Ocugen, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases.
Featured Article: Penny Stocks, What You Need To Know
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.